Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis

John Denyer, Ivan Prince, Emma Dixon, Penny Agent, Jennifer Pryor, Margaret Hodson, John Denyer, Ivan Prince, Emma Dixon, Penny Agent, Jennifer Pryor, Margaret Hodson

Abstract

Background: Adaptive Aerosol Delivery (AAD) systems provide efficient drug delivery and improved lung deposition over conventional nebulizers by combining real-time analyses of patient breathing patterns and precisely timed aerosol delivery. Delivery and deposition are further enhanced by breathing techniques involving slow, deep inhalations.

Methods: This exploratory study assessed the acceptability of slow, deep inhalations in 20 patients with cystic fibrosis (CF) during up to eight simulated nebulizer treatments with the I-neb AAD System. The breathing maneuver, Target Inhalation Mode (TIM) breathing, involved the lengthening of the patient's inhalation time over successive breaths with guidance from auditory and tactile (vibratory) feedback from the device.

Results: At the end of the first treatment, most patients felt that the instructions were easy to understand (90%) and that the vibratory feedback was pleasant (65%). Half of the patients found the procedure to be comfortable. At the end of the final treatment, most patients felt that the breathing maneuver was easy to understand (90%) and use (80%), but that the duration of the breath was too long (100%). Logged data revealed that 90% of patients were able to comply with the breathing maneuver. The two patients unable to comply had a forced vital capacity of <1.75 L. The average treatment time decreased from 288.4 to 141.6 sec during the first and final treatments, respectively.

Conclusions: This study provides preliminary evidence of the acceptability of the TIM breathing maneuver in patients with CF and their ability to perform repeated TIM breathing during simulated nebulizer therapy with the I-neb AAD System.

Figures

FIG. 1.
FIG. 1.
The figure shows the study equipment, which consisted of a customized I-neb AAD System connected to a personal computer operating the I-neb AAD System software. A flow restrictor, a pneumotach, and a vibration device had been built into the customized I-neb AAD System handset.
FIG. 2.
FIG. 2.
A graphic presentation of breath patterns for Tidal Breathing Mode (TBM) and Target Inhalation Mode (TIM).
FIG. 3.
FIG. 3.
The figure shows a comparison between the patients' baseline forced vital capacity (FVC) and their opinions on breath length after the first treatment.
FIG. 4.
FIG. 4.
A graphic presentation of logged data for one of the patients including inhalation time (♦), pulse time (▪), and Inhalation Target Time (▴) data. The data were collected over five placebo treatments.
FIG. 5.
FIG. 5.
A graphic presentation of the mean treatment times and the mean number of inhalations during the eight study treatments. The number of inhalations decreased in parallel with the mean treatment time.

References

    1. Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, editor; Geddes DM, editor. Cystic Fibrosis. Chapman and Hall; London: 1995. pp. 1–13.
    1. Sheppard MN. The pathology of cystic fibrosis. In: Hodson ME, editor; Geddes DM, editor. Cystic Fibrosis. Chapman and Hall; London: 1995. pp. 131–149.
    1. Geller DE. Choosing a nebulizer for cystic fibrosis applications. Curr Opin Pulm Med. 1997;3:414–419.
    1. Geller DE. Eigen H. Fiel SB. Clark A. Lamarre AP. Johnson CA. Konstan MW. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol. 1998;25:83–87.
    1. Le Brun PPH. de Boer AH. Gjaltema D. Hagedoorn P. Heijerman HGM. Frijlink HW. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer. Int J Pharm. 1999;189:205–214.
    1. Ramsey BW. Pepe MS. Quan JM. Otto KL. Montgomery AB. Williams-Warren J. Vasiljev KM. Borowitz D. Bowman CM. Marshall BC. Marshall S. Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23–30.
    1. Katz SL. Ho SL. Coates AL. Nebulizer choice for inhaled colistin treatment in cystic fibrosis. Chest. 2001;19:250–255.
    1. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 2001;120:107S–113S.
    1. Garcia-Contreras L. Hickey AJ. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv Drug Deliv Rev. 2002;54:1491–1504.
    1. Ryan G. Mukhopadhyay S. Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. The Cochrane Database of Systematic Reviews. 2003;(3. Art. No.):CD001021. doi: 10.1002/14651858.CD001021.
    1. Hagerman JK. Hancock KE. Klepser ME. Aerosolised antibiotics: a critical appraisal for their use. Expert Opin Drug Deliv. 2006;3:71–86.
    1. Touw DJ. Brimicombe RW. Hodson ME. Heijerman HGM. Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J. 1995;8:1594–1604.
    1. Conway SP. Pond MN. Hamnett T. Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax. 1996;51:29–33.
    1. Wilson AM. Nikander K. Brown PH. Drug device matching. Eur Respir Rev. 2000;10(76):558–566.
    1. Hunter V. The daily grind and how to stay sane as a mother of two children with cystic fibrosis. J R Soc Med. 2003;96(Suppl 43):51–56.
    1. Nikander K. Drug delivery systems. J Aerosol Med. 1994;7(Suppl 1):S19–S24.
    1. Mukhopadhyay S. Staddon GE. Eastman C. Palmer M. Rhys Davies E. Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994;194(88):203–211.
    1. Saari SM. Vidgren MT. Koskinen MO. Turjanmaa VMH. Waldrep JC. Nieminen MM. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest. 1998;113:1573–1579.
    1. Nikander K. Adaptive aerosol delivery: the principles. Eur Respir Rev. 1997;7(51):385–387.
    1. Denyer J. Adaptive aerosol delivery in practice. Eur Respir Rev. 1997;7:388–389.
    1. Denyer J. Nikander K, and Smith NJ: Adaptive Aerosol Delivery (AAD®) technology. Expert Opin Drug Deliv. 2004a;1:165–176.
    1. Byrne NM. Keavey PM. Perry JD. Gould FK. Spencer DA. Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch Dis Child. 2003;88:715–718.
    1. Kastelik JA. Wright GA. Aziz I. Davies M. Avery GR. Paddon AJ. Howey S. Morice AH. A widely available method for the assessment of aerosol delivery in cystic fibrosis. Pulm Pharmacol Ther. 2002;15:513–519.
    1. Smaldone GC. Assessing new technologies: patient-device interactions and deposition. Respir Care. 2005;50:1151–1158.
    1. Prince I. Seamark D. Pinnuck M. Hinch S. Denyer J. Conway J. Evaluation of a guided breathing manoeuvre for nebulised inhaled therapy. In: Byron PR, editor; Dalby RN, editor; Peart J, editor; Suman JD, editor; Farr SJ, editor. Respiratory Drug Delivery IX. Virginia Commonwealth University; Richmond, VA: 2004. pp. 315–318.
    1. Nikander K. Prince I. Coughlin SR. Warren S. Taylor G. Lung deposition of 99mTc-DTPA delivered with I-neb® Adaptive Aerosol Delivery (AAD®) system. Eur Respir J. 2007:545s.
    1. Quanjer PH. Tammeling GJ. Cotes J. Pedersen R. Peslin R. Yernault J-C. Lung volumes and forced ventilatory flows: Report of Working Party, Standardization of lung function tests, European Community for Steel and Coal; Official statement of the European Respiratory Society. Eur Respir J. 1993;6(Suppl 16):5–40.
    1. American Thoracic Society: Snowbird Workshop on standardization of spirometry. Am Rev Respir Dis. 1979;119:831–838.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera